NeoGenomics, Inc Announces Chairman Invited to Speak at Conference in D.C.
"The Next Phases of Pharmacogenomics" was the topic of the meeting and NeoGenomics was an invited participant to discuss the research initiatives that Dr. Dent has set forth and to offer insights into bridging the gap between practical clinical medicine and pharmacogenomics research.
Leaders in genetics and pharmacology research attended the meeting including representatives from Celera Diagnostics, Novartis, Spectral Genomics, NeoPharm, Inc., Xenon Genomics, Astra Zeneca, Roche Consulting, Salmedix Inc, U.S. FDA, Egeen International Corporation, Congent Therapeutics, Inc., and CeMines, Inc.
"I was honored to be one of the speakers at the 2004 Pharmacogenomic conference. NeoGenomics is in the early stages of its research and development activity and I was excited to be able to speak about our current and upcoming research activities" stated Dr. Michael Dent.
NeoGenomics has was been working to identify biomarkers for female disease such as preeclampsia and ovarian cancer. NeoGenomics uses MALDI TOF mass spectroscopy to identify proteins that are specific and sensitive to each disease. NeoGenomics has established ties with Florida Gulf Coast University, has a number of research collaborators in the region and is looking to increase its research activity in 2005.
About NeoGenomics, Inc.
NeoGenomics, Inc. has established a state-of-the-art genetic/diagnostic or "Genostics" laboratory in Ft. Myers, FL. The Company's principle operations include providing cytogenetic and molecular biology diagnostic testing services to the oncology and perinatology sectors of the healthcare industry. The Company also conducts research activities for the early diagnosis of women's diseases, such as ovarian cancer, as well as diseases in prenates and infants. For additional information on NeoGenomics, please visit our web site at www.neogenomics.org.
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, expand its presence into other geographies, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
Contact NeoGenomics, Inc. Mr. Steven C. Jones, 239/768-0600 firstname.lastname@example.org
Posted: October 2004